Table 1.
Clinical and MRI parameters at diagnosis and at the enrolment (whole population)
| OCB+ | OCB− | Whole group | p value | |
|---|---|---|---|---|
| N (f/m) | 50 (34/16) | 40 (28/12) | 90 (62/28) | 0.511 |
| Age (years) | 42.5 ± 10.4 (19–67) | 42.4 ± 11.2 (17–69) | 42.5 ± 10.7 (17–69) | 0.943 |
| Years from onset to diagnosis | 3.0 ± 5.1 (0–21) | 2.6 ± 3.9 (0–17) | 2.8 ± 4.6 (0–21) | 0.356 |
| Years from diagnosis to enrolment | 7.8 ± 5.2 (0–20) | 7.9 ± 6.4 (0–22) | 7.9 ± 5.7 (0–22) | 0.918 |
| Years from onset to enrolment (disease duration) | 10.8 ± 7.0 (1–31) | 10.5 ± 7.3 (1–29) | 10.7 ± 7.1 (1–31) | 0.878 |
| EDSS at diagnosis | 1.5 (0–3.0) | 1.0 (0–3.5) | 1.5 (0–3.5) | 0.645 |
| EDSS at enrolment | 2.8 (1.0–8.0) | 1.5 (0–6.5) | 2.0 (1.0–8.0) | <0.0001 |
| RRMS/SPMS at enrolment | 35/15 | 36/4 | 71/19 | 0.018 |
| Time to SPMS transition in months | 123 ± 23 (98–187) | 183 ± 13 (165–198) | 136 ± 33 (98–198) | <0.0001 |
| Cognitive impairment CN/mCI/sCI | 30/9/11 | 34/5/1 | 64/14/12 | 0.013 |
| CL number at enrolment | 6.1 ± 6.1 (0–24) | 2.2 ± 2.8 (0–11) | 4.4 ± 5.3 (0–24) | <0.0001 |
| WMLV at enrolment (cm3) | 7.1 ± 3.6 (1.1–16.4) | 6.5 ± 4.1 (1.3–18.1) | 6.8 ± 4.0 (1.1–18.1) | 0.258 |
| Treatment until now | ||||
| None | 0 | 5 | 5 | 0.033 |
| Only 1° linea | 34 | 28 | 62 | |
| At least 2° linea | 11 | 6 | 17 | |
| At least 3° linea | 5 | 1 | 6 | |
EDSS Expanded Disability Status Scale, RRMS relapsing-remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, CN cognitively normal, mCI mild cognitive impairment, sCI severe cognitive impairment, CL cortical lesion, WML white matter lesion
Data are reported as mean ± standard deviation (range). For the EDSS, median and (range) are provided
a1° line drugs: IFN-beta, GA, azathioprine; 2° line drugs: fingolimod, natalizumab; 3° line drug: cyclophosphamide, mitoxantrone